A tale of two receptors:Insulin and insulin-like growth factor signaling in cancer

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 667-669

  Yee, Douglas ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIGITUMUMAB; GLUCOSE; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR; LINSITINIB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRAZINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; EVIDENCE BASED MEDICINE; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; FEMALE; MALE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMIDAZOLES; MALE; NEOPLASMS; PYRAZINES;

EID: 84923124115     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2056     Document Type: Article

References (13)

1. Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res 2015;21:693-700.
2. Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlinn J, et al. A phase I study of continuous oral cosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 2015;21:701-11.
3. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012;104:975-81.
4. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014;32:2059-66.
5. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012;41:425-43, vii-viii.
6. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70: 741-51.
7. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40.
8. Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988;48: 1026-9.
9. Vijayakumar A, Novosyadlyy R,WuY, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 2010;20:1-7.
10. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulinlike growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7.
11. Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res 2009;15:2840-9.
12. Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat 2012; 133:117-26.
13. McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res 2013;19:4282-9.